<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947670</url>
  </required_header>
  <id_info>
    <org_study_id>RE-ADAPT-HF (2021)</org_study_id>
    <nct_id>NCT04947670</nct_id>
  </id_info>
  <brief_title>A Prospective, Multicenter, Randomized, Blinded, Sham-controlled, Feasibility Study of Renal Denervation in Patients With Chronic Heart Failure</brief_title>
  <acronym>RE-ADAPT-HF</acronym>
  <official_title>A Prospective, Multicenter, Randomized, Blinded, Sham-controlled, Feasibility Study of Renal Denervation in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universität des Saarlandes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The renin-angiotensin-aldosterone axis has been found to be a key system involved in heart&#xD;
      failure disease progression and it may be inhibited by renal sympathetic denervation.&#xD;
      Therefore, a clear need exists for further strategies to beneficially manipulate the&#xD;
      sympathetic activation that is characteristic of the heart failure disease process.&#xD;
&#xD;
      The combined experience in the pilot studies and the EU randomized, controlled study&#xD;
      indicates that the Paradise Catheter System can safely denervate renal sympathetic nerves of&#xD;
      the kidney without significant periprocedural complications.&#xD;
&#xD;
      Preliminary results of a pilot study of catheter-based renal denervation in a small number of&#xD;
      CHF patients did not show evidence of safety issues but suggest improvements in CHF symptoms.&#xD;
      This trial will explore the safety and feasibility of renal denervation in a significantly&#xD;
      higher number of patients with chronic heart failure. Both inter-individual and&#xD;
      intra-individual controls will be used in order to obtain sufficient data and to in order to&#xD;
      enable both treatment and control group to receive renal denervation.&#xD;
&#xD;
      Additionally, this feasibility trial to describe the safety and feasibility of renal&#xD;
      denervation in patients with elevated sympathetic activity as in patients with chronic heart&#xD;
      failure, will further the understanding of the role of renal nerves in the control of chronic&#xD;
      heart failure and the pathogenesis of both ventricular remodeling and cardio-renal syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, double-blind, sham-controlled, multicenter, feasibility study. Patients will be screened for meeting eligibility and centrally randomized to receive either renal denervation or sham procedure. Best medical therapy will be provided to all patients. Optional cross-over after 12 months for sham-group patients. Thus, there is an intra-individual control in patients of the control group and all of the randomized patients are entitled to receive study treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Unblinded interventionist, unblinded intervention team and blinded study team at each center, blinded patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>6 Minute Walk Test</measure>
    <time_frame>6 months</time_frame>
    <description>Change in 6-min walk distance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>6 months</time_frame>
    <description>Change in plasma NT-proBNP values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KCCQ</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Overall Summary Score measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Chronic Heart Failure Questionnaire Self-Administered Standardized format (CHQ-SAS) dyspnea score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>6 months</time_frame>
    <description>chronic eGFR slope defined as eCRF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Cardio-Renal Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation and maintenance of heart failure medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham intervention, maintenance of heart failure medications with option for cross-over renal denervation treatment after 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal arteriography followed by renal denervation</intervention_name>
    <description>Renal arteriography followed by renal denervation</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Renal arteriography</intervention_name>
    <description>Renal arteriography only</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with CHF diagnosed for at least 3 months prior to consent&#xD;
&#xD;
          -  6-min walk distance ≤350 m&#xD;
&#xD;
          -  NYHA Class II-III symptoms of CHF&#xD;
&#xD;
          -  Systolic left ventricular dysfunction as assessed by echocardiogram with left&#xD;
             ventricular ejection fraction &lt;45%&#xD;
&#xD;
          -  eGFR calculated (CKD-EPI) &gt;30 ml/min/1.73 m2&#xD;
&#xD;
          -  NT-pro-BNP &gt;450 pg/ml, &gt;900 pg/ml for patients with atrial fibrillation&#xD;
&#xD;
          -  Optimal medical drug therapy according to current guidelines for CHF management. This&#xD;
             medication may include loop diuretics, ACEi/ARBs, ARNI, SGLT-2 inhibitors, aldosterone&#xD;
             antagonists, and beta-blockers, unless intolerance to any of the above is documented.&#xD;
             Treatment for HF must be stable (including drug and dose) for 4 weeks prior to&#xD;
             randomization, except diuretics (2 weeks stable)&#xD;
&#xD;
          -  Appropriate use of medical devices such as an implantable cardioverter defibrillator&#xD;
             (ICD) or a cardiac resynchronization therapy (CRT) consistent with prevailing local or&#xD;
             international guidelines, and if a device is required, it must have been implanted for&#xD;
             at least 3 months prior to consent for CRT and 1 month prior to consent for ICD&#xD;
&#xD;
          -  Age ≥18 years and ≤80 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal arterial anatomy that is ineligible for treatment&#xD;
&#xD;
          -  Myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within&#xD;
             12 weeks prior to consent&#xD;
&#xD;
          -  Office systolic BP at screening &lt;90 mmHg&#xD;
&#xD;
          -  Clinically significant cardiac structural valvular disease, unless corrected by a&#xD;
             properly functional prosthetic valve&#xD;
&#xD;
          -  Hypertrophic obstructive cardiomyopathy&#xD;
&#xD;
          -  Major surgery in the previous 12 weeks prior to consent&#xD;
&#xD;
          -  Hospitalization for decompensated CHF in the &lt;30 days prior to consent&#xD;
&#xD;
          -  Parenteral therapy for the treatment of CHF&#xD;
&#xD;
          -  Respiratory support (excluding sleep apnea therapy)&#xD;
&#xD;
          -  Left ventricular assist or planned heart transplantation&#xD;
&#xD;
          -  Patient is pregnant, nursing, or planning to be pregnant&#xD;
&#xD;
          -  Ineligibility to consent&#xD;
&#xD;
          -  Primary pulmonary hypertension (systolic PAP &gt;70 mmHg)&#xD;
&#xD;
          -  BMI ≥40 kg/m²&#xD;
&#xD;
          -  Any condition that would contraindicate the assessment of 6-min walk distance.&#xD;
&#xD;
          -  Patient has type I diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Mahfoud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saarland University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felix Mahfoud, MD</last_name>
    <phone>+49-6841-16-15911</phone>
    <email>Felix.Mahfoud@uks.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saarland University Medical Center, Department for Internal Medicine III</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Felix Mahfoud, MD</last_name>
      <phone>+49-6841-16-15911</phone>
      <email>Felix.Mahfoud@uks.eu</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

